Tissue Regeneration Therapeutics Receives Latest Notice of Patent Grant from the United States Patent Office

Toronto, Canada, April 6th 2017: Tissue Regeneration Therapeutics Inc. (TRT) today
announced it has received notice from the United States Patent and Trademark Office that
its patent: Progenitor Cells from Wharton’s Jelly of Human Umbilical Cord, was
grated on April 4th, 2017 as US patent 9611456, a continuation of U.S. patent application Ser.
No. 12/482,963.

The issuance of this latest patent adds to the extensive international TRT patent portfolio
and is an important milestone further demonstrating the company’s commitment to
protecting and expanding its valuable intellectual property.

TRT is a progressive biotechnology company with a focus on the commercial development
of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC) platform technology
and its TXP family of cell therapy products. TRT has discovered the world’s richest source
of mesenchymal stromal/stem cells (MSCs) with potent regenerative, angiogenic, anti-
inflammatory, and immuno-regulatory properties. Unique advantages of the TRT HUCPVC
platform technology are founded on the highly enriched source of these important cells
compared to other tissue sources. Specifically, HUCPVCs represent high cell yields at
harvest from tissue normally discarded at birth; high frequencies of mesenchymal stromal
cells within the harvested population, their increased biological potential compared to cells
derived from adult tissues and their inexhaustible supply.

About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the commercial
development of their patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology and its TXP cell therapy products. TRT is the only company in the
world to have issued and allowed patents in the USA, Europe and Australasia, for extraction
of these unique cells from umbilical cord tissue. TRT provides license opportunities to
collaborating partner companies in the regenerative medicine, defense, and family banking
sectors. Additional information is available at

Write a comment